DermTech, Inc. (DMTK)
Company Description
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States.
It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways.
In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies.
The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
| Country | United States |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 255 |
| CEO | Dr. John D. Dobak M.D. |
Contact Details
Address:
11099 N. Torrey Pines Road, Suite 100 La Jolla, California 92037 United States | |
| Phone | 858-450-4222 |
| Website | dermtech.com |
Stock Details
| Ticker Symbol | DMTK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651944 |
| CUSIP Number | 24984K105 |
| ISIN Number | US24984K1051 |
| Employer ID | 84-2870849 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Dr. John D. Dobak M.D. | President, Chief Executive Officer and Director |
| Kevin Sun M.B.A. | Chief Financial Officer, Treasurer and Secretary |
| Claudia Ibarra | Chief Operating Officer |
| Ray Akhavan J.D. | General Counsel |
| Todd Michael Wood | Chief Commercial Officer |
| William W. Zondler | Chief Information Officer |
| Steve E. Kunszabo | Senior Director of Investor Relations |
| Jennifer Eilemberg | Chief Compliance Officer |
| Ray Bassi | Vice President of Sales |
| Dr. Burkhard Jansen M.D. | Chief Medical Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2023 | 8-K | Current Report |
| Mar 3, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 2, 2023 | 10-K | Annual Report |
| Mar 2, 2023 | 8-K | Current Report |
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 3, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 15, 2022 | 8-K/A | [Amend] Current report |
| Nov 14, 2022 | 8-K | Current Report |
| Nov 8, 2022 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 3, 2022 | 10-Q | Quarterly Report |